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Efforts to understand hepatocellular carcinoma (HCC) are at a
fever pitch because of the epidemic incidence of the disease
and the paradigm-shifting SHARP trial [1], which established this
neoplasm as a tractable target for molecular therapies. As a
result, identifying new molecular targets and improving the diag-
nosis of early disease are major points of attack, and two articles
from this month’s issue address these important topics.
The study by Tomimaru et al. reports detection of microRNA-
21 (miR-21) as a biomarker of disease in hepatocellular carci-
noma, which is similar to previous reports detecting circulating
miRNAs as markers of HCC [2,3], including one also describing
serum miR-21 [3]. The Tomimaru study, like the previous miR-
21 report [3], notes elevated levels both in chronic hepatitis as
well as HCC. The Tomimaru study suggests that elevated miR-
21 is comparable to alpha fetoprotein (AFP) in distinguishing
chronic hepatitis from HCC, and could improve the diagnostic
power of AFP. Supporting the contention that elevated miR-21
is derived directly from HCC, plasma levels consistently
decreased after hepatic resection for HCCs in 126 patients, the
majority of whom had chronic HCV infection. However, the levels
did not correlate with any of the conventional staging systems or
standard clinical parameters, and in aggregate the data suggest
that miR-21 may aid in the diagnosis of HCC but is not suitable
for screening.
While the Tomimaru study is unlikely to have a major impact
on understanding HCC disease pathogenesis or improving diag-
nosis, it introduces the broader issue of microRNA biology, and
the emerging roles of circulating miRNAs in malignant and
benign liver diseases. The astonishing growth in our understand-
ing of miRNAs since the Nobel prize-winning work of Fire and
Mello in 1998 [4] continues to yield enormous scientiﬁc and clin-
ical dividends, including a substantial reﬁnement of our under-
standing of cancer pathogenesis [5], as well as prospects for
new therapies [6]. MicroRNAs are endogenous non-coding RNAs
whose highly regulated processing yields cytoplasmic RNA frag-
ments (20–22 nt) that bind to speciﬁc seed sites in a range of tar-
get RNAs, thereby altering RNA stability, and/or translational
activity. MicroRNAs in cancer may be up- or down-regulated
and thereby may enhance tumor growth by antagonizing tumor
suppressors or increasing the expression of growth-promoting
genes [7]. They are part of a rapidly growing family of non-codingJournal of Hepatology 20
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peting endogenous), lincRNA (large intervening non-coding),
snoRNAs (small nucleolar), and PiwiRNA (P-element induced
wimpy testis). Clearly, the ﬁeld has come a long way from the
simple central dogma of biology, which was originally deﬁned as
‘‘DNA to RNA to Protein’’.
While changes in individual miRNAs in HCC have been exten-
sively described, altered expression patterns of miRNA clusters
are providing a more comprehensive picture of the their role in
the disease, and have facilitated the identiﬁcation of new thera-
peutic targets [9–11]. For example, miR-517a recently emerged
from such a global analysis, based on its elevated expression in
an aggressive subtype of human disease, and its contribution to
tumorigenesis in an animal model [9].
Coming on the heels of studies exploring miRNAs in patho-
genesis have been efforts to detect miRNAs in serum or plasma
of patients with a range of cancers as potential biomarkers [12],
as in the Tomimaru study in this issue of the Journal. The miRNAs
detectable in serum are remarkably stable to a variety of physical
conditions including boiling, freeze–thaw, and extreme pH,
which has led to the discovery that these molecules can be
sequestered within small membrane vesicles (50–90 nm) called
exosomes. MicroRNAs within exosomes are not only potential
disease markers, but can be biologically active at distant sites
[13]. Indeed, HCC cells in culture can produce miRNA-containing
exosomes that modulate intracellular signaling of neighboring
cells [14]. Circulating miRNAs are not only present in malignant
liver diseases, but also in chronic injury, since a recent study
has demonstrated that a miRNA (miR-29a) derived from acti-
vated stellate cells is detectable in human serum, and its level
decreases with advancing ﬁbrosis [15].
Despite these exciting translational prospects, there remain
more questions than answers in attempting to exploit miRNA
biology in clinical medicine. Are all miRNAs that are detected in
serum sequestered within exosomes? Are circulating miRNA-
containing exosomes present in humans, and if so how can they
be quantiﬁed? What is the normal range of serum miRNA levels
and quantity of exosomes? What are the mechanisms underlying
miRNA release from cancer and non-cancer cells, and how will
answering this question advance our understanding of disease
pathogenesis? Given their ability to modulate many human
genes simultaneously, can miRNAs help us understand the differ-
ence between benign neoplasia and liver cancer? And ﬁnally, will
combinations of miRNAs prove more useful as biomarkers of dis-
ease detection or staging than individual ones?12 vol. 56 j 1–3
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Whereas the miRNA study investigated a host determinant of
HCC, the study by Lee et al. from Korea in this issue of the Journal
explored a viral determinant. This study of HBV stop codons in
the HBV surface antigen gene traces its conceptual roots to the
human papilloma virus (HPV) ﬁeld, where some viral strains
are known to be far more oncogenic than others. The question
of whether hepatitis viruses have oncogenic strains, mutant
forms, and sequence variants has recently become a hot research
topic, stimulated in part by the discovery of mutations in the HCV
core gene that are associated with increased HCC risk [16]. The
study by Lee et al. provides an interesting mechanistic link
between the increased risk of HCC among Asian patients with
HBV genotype C and HBV mutations [17–19]. Genotype C, which
is most common in Asia, has been associated with an increased
risk of delayed HBeAg seroconversion, higher viral replication,
and increased risk of ﬁbrosis, cirrhosis, and HCC [17]. Among
their genotype C patients, the Korean investigators have per-
formed extensive viral sequence analysis to study the clinical sig-
niﬁcance of a premature stop at codon 182 in the S gene, which
creates a truncated S protein. In 275 patients in whom HBV
DNA could be ampliﬁed, 73 (26.5%) harbored variants encoding
one of the two possible stop codons (UGA or UAG) at position
182 of the HBV surface antigen gene. In most cases, the virus pop-
ulation also included variants with the wild type gene. Variants
encoding the stop codons were more common in patients with
advanced liver disease (HCC and/or cirrhosis) than in patients
without cirrhosis. Interestingly, these patients had lower HBV
levels, which is surprising because higher levels of HBV replica-
tion are usually associated with more progressive liver disease.
The authors speculate that these paradoxical effects on viral rep-
lication result from increased ER stress and an unfolded protein
response (UPR) in infected cells, as well as impaired formation
of virions and loss of infectivity. The authors also demonstrate
that cell growth was increased in HCC lines stably expressing
the stop codon variant, compared to those with the wild type
sequence, which was linked to increased cell cycle progression
and colony forming ability, and reduced p53, and p21 expression,
proteins which block cell growth.
These ﬁndings raise tantalizing clues that merit further
exploration. Although the authors imply that mutant viruses
are driving liver disease progression, this cross-sectional analy-
sis does not allow one to determine whether the mutations
arose before or after the advanced liver injury. Also, the sug-
gestion that the 182 stop variant induces more ER stress and
UPR is eminently testable in cultured HCC cells, although levels
of viral protein expression should be comparable to those
observed in vivo rather based upon an over-expression system
in which protein levels exceed those of the native infection. In
analyzing the speciﬁc sequences of codon 182, a UGA stop
codon was much more common than the UAG codon, even
though both require a single mutation of the wild type codon
(UGG-tryptophan). Signiﬁcantly, the UGA stop codon introduces
a mutation into the overlapping polymerase gene, while the
UAG mutation does not. Absent some selection pressure, one
would expect the UAG mutation to be more common than
the UGA mutation, because a virus would typically want to
preserve its polymerase gene. What selection pressure could
favor a mutation in the polymerase gene? One well-known
force that can drive such mutations is the use of antiviral drugs
such as nucleoside reverse transcriptase inhibitors. The authors
do not provide any information about the treatment history of2 Journal of Hepatology 2the patients, but it raises concern that the use of antiviral
drugs favors the creation of viruses that could interfere with
the cell’s ability to process proteins.
The mechanisms leading to increased cell growth are equally
intriguing but obscure. The link to altered p53 is reminiscent of
many studies of the HBV X protein [20], which initially were pla-
gued by concerns about whether levels of X protein expression in
cell culture models were appropriate. From a molecular/epidemi-
ologic perspective, it would be interesting to know whether the
entire risk of increased HCC associated with genotype C can be
attributed to the subset of patients with this mutation, or
whether other features of the genotype are also permissive for
HCC development. In particular, can the increased disease activ-
ity and advanced ﬁbrosis associated with this genotype confer
an independent risk of HCC? Also, it would be interesting to know
where the polymerase gene mutations map relative to the vari-
ous domains of this protein.
Finally, the stop codonmutations are associated with low viral
load but they are not associated with loss of HBeAg expression,
which is atypical. If the association between these mutations
and adverse clinical outcomes is conﬁrmed in future studies, pro-
viders will need to be vigilant for patients with low HBV viral
load who are HBeAg positive. These patients may harbor stop
codons that confer an increased risk of cirrhosis and HCC.
Together, these two studies pave more inroads in unraveling
the mysteries of HCC, and further highlight the disease’s
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